Figure 1 The multidomain structure of c-MET and its ligand, HGF

Slides:

Advertisements

Similar presentations

Signal Transduction Mechanisms Underlying Underlying Growth Control and Oncogenesis Ronit Sagi-Eisenberg Dept. of Cell and Developmental Biology Sackler.

Advertisements

Fundamentals of Cell Biology

Signal Response and Amplification

Transduction of Extracellular Signals Specific receptors in plasma membranes respond to external chemicals (ligands) that cannot cross the membrane: hormones,

Lung Cancer Tumour Markers

Figure 1. Functional classification of positive-acting transcription factors. Major functional groups are shown in black; specific examples are illustrated.

Figure 1 CTLA-4 and PD-1–PD-L1 immune checkpoints

Figure 2 Crosstalk between TGF-β/Smad and other pathways in tissue fibrosis Figure 2 | Crosstalk between TGF-β/Smad and other pathways in tissue fibrosis.

Figure 2 Immune-escape mechanisms of CTCs in the peripheral blood

Figure 5 Schematic illustration of different clinical trial designs

Figure 4 The mechanistic link between the epithelial-to-mesenchymal

TGFb –Superfamily Proteins

Figure 2 Signalling pathways and physiological domains that are

Figure 1 Four nodes to target when inducing anti-tumour immunity

Figure 1 Key time points in the discovery and development of imatinib for the treatment of chronic myeloid leukaemia (CML) and gastrointestinal stromal.

Targeting MET in Lung Cancer: Will Expectations Finally Be MET?

Figure 1 Chimeric antigen receptor (CAR) structures

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 3 Natural and imatinib-induced immunosurveillance in gastrointestinal tumours (GISTs) Figure 3 | Natural and imatinib-induced immunosurveillance.

Figure 1 Classical and non-classical models of the cell cycle in RB1-proficient cells Figure 1 | Classical and non-classical models of the cell cycle in.

Figure 3 The cell cycle and the role of CDK4/6 inhibition

Nat. Rev. Endocrinol. doi: /nrendo

Cell to Cell Communication via Enzyme Linked Receptors

Nat. Rev. Clin. Oncol. doi: /nrclinonc

cMET Exon 14 Skipping: From the Structure to the Clinic

Figure 2 Therapeutic targeting of the PI3K/AKT/mTOR pathway

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 1 CAR-T-cell design

Figure 1 A schematic representation of the HER2 signalling pathway

Figure 4 Combination immunotherapeutic approaches with imatinib

دکتر مجیری داروساز متخصص فارماکولوژی

Figure 2 Oestrogen receptor signalling pathways

Figure 2 HGF/c-MET signalling pathway

Nat. Rev. Rheumatol. doi: /nrrheum

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 1 Therapeutic targeting of the B-cell receptor (BCR)

Volume 130, Issue 2, Pages (July 2007)

Figure 4 Angiogenic signalling network and inhibition by antiangiogenic drugs Figure 4 | Angiogenic signalling network and inhibition by antiangiogenic.

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 3 Structure of different types of T-cell-engaging antibodies

Figure 5 The mechanism underlying epithelial-to-mesenchymal

Nat. Rev. Urol. doi: /nrurol

Figure 3 Inhibitors of the IL-6/JAK/STAT3 signalling pathway

Jo-Ellen Murphy, Caroline Robert, Thomas S. Kupper

Figure 1 CD36 structure and post-translational modifications

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Specificity in Signal Transduction

A) RON tyrosine kinase receptor structure; highlighted are the two somatic mutations detected in brain secondary lesions from lung cancers (R1136C and.

Met as a therapeutic target in HCC: Facts and hopes

Signaling Network Model of Chromatin

Monica Kong-Beltran, Jennifer Stamos, Dineli Wickramasinghe

Smad proteins and transforming growth factor-β signaling

Proteins Kinases: Chromatin-Associated Enzymes?

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Clin. Oncol. doi: /nrclinonc

SOCS Proteins, Regulators of Intracellular Signaling

Yan Feng, MD, Praveena S. Thiagarajan, PhD, Patrick C. Ma, MD

Figure 4 Radiogenomics analysis can reveal relationships

Platelet-derived growth factor (PDGF) signalling pathway.

Figure 3 Determination of the primary site

Components and outcomes of selected TNF-superfamily signalling pathways. Components and outcomes of selected TNF-superfamily signalling pathways. (Left)

Figure 2 Signalling downstream of the IL-6 receptor

The PTH receptor type 1. The PTH receptor type 1. This “snake” diagram of the human the PTHR1 illustrates the receptor's 593 amino acids in a topological.

Figure 4 Molecular signalling and immunological

Volume 7, Issue 1, Pages 1-11 (July 1997)

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 2 Mechanisms of RET activation in cancer

Cell Signaling by Receptor Tyrosine Kinases

Toll-like receptors, adapter proteins, and signaling molecules.

Presentation transcript:

Figure 1 The multidomain structure of c-MET and its ligand, HGF Figure 1 | The multidomain structure of c-MET and its ligand, HGF. a | The domain structure of c-MET. The extracellular domain comprises a large N-terminal semaphorin (SEMA) domain, which folds into a seven-bladed β-propeller structure, a plexin, semaphorin, and integrin (PSI) domain and four immunoglobulin-like IPT (immunoglobulin- like regions in plexins and transcription factors) domains (IPT1–4), which comprise four disulfide-linked loop structures. The intracellular domain constitutes a juxtamembrane domain (JM), containing Ser975, which negatively regulates c-MET kinase activity upon phosphorylation, and Y1003, which is involved in endocytosis, a tyrosine kinase (TK) domain, containing Y1234 and Y1235, which upregulate kinase activity upon transautophosphorylation and a c-terminal multifunctional docking site (MFDS), which mediates recruitment of cytoplasmic signalling molecules and adaptor proteins via Y1349 and Y1356. b | Domain structure of HGF, comprising the N-terminal (N) hairpin- loop, four kringle domains (K1–K4) of the α-chain, and the c-terminal serine proteinase homology (SPH) domain of the β-chain, which is homologous to serine proteinases, but lacks proteolytic activity. Bradley, C. A. et al. (2017) Targeting c‑MET in gastrointestinal tumours: rationale, opportunities and challenges Nat. Rev. Clin. Oncol. doi:10.1038/nrclinonc.2017.40